<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04943224</url>
  </required_header>
  <id_info>
    <org_study_id>TRAM</org_study_id>
    <nct_id>NCT04943224</nct_id>
  </id_info>
  <brief_title>Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment</brief_title>
  <acronym>TRAM</acronym>
  <official_title>Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients With Refractory Histiocytosis or After the Failure of Vemurafenib Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Raciborska</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maria Sklodowska-Curie Institute - Oncology Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Łukasiewicz Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wrocław University of Environmental and Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Mother and Child, Warsaw, Poland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, interventional, open, randomized, single-center, non-commercial clinical trial&#xD;
      to optimize treatment and dosage of trametinib in juvenile patients with histiocytosis&#xD;
      resistant to conventional therapy and without the BRAF gene mutation or after the failure of&#xD;
      vemurafenib treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      TRAM clinical study is part of the POL HISTIO project. The POL HISTIO project is a&#xD;
      non-commercial clinical trial aimed at optimizing the diagnosis and treatment of juvenile&#xD;
      patients with histiocytosis. The project objectives are defined as follows: 1) to estimate&#xD;
      the nature and frequency of mutations in patients with histiocytosis in both tumor tissues&#xD;
      and free-circulating DNA; 2) to compare molecular test results with clinical data; 3) to&#xD;
      evaluate the diagnostic usefulness of the status of molecular analysis (MRD) as a prognostic&#xD;
      factor compared with other recognized factors; 4) in the case of failure of conventional&#xD;
      therapy - to modify treatment and to apply targeted treatment, based on molecular status of&#xD;
      gene mutation. The project is intended to include patients from all over Poland.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2021</start_date>
  <completion_date type="Anticipated">June 23, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2026</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>2 years</time_frame>
    <description>Event-free survival (EFS) was defined as the time interval from the date of diagnosis to the date of disease progression, recurrence, second malignancy, death or to date of last follow-up for patients without events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Molecular relapse (in ct DNA)</measure>
    <time_frame>2 years</time_frame>
    <description>Molecular relapse was defined as the time interval from the date of any mutation negativization to the date of positive results of any mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to negative mutation test results (in ct DNA)</measure>
    <time_frame>2 years</time_frame>
    <description>Time to negative mutation test results (in ct DNA) was defined as the time interval from the date of positive mutation to the date of negative results of any mutation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Histiocytosis</condition>
  <arm_group>
    <arm_group_label>R1 time of trametinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with negative status of any mutation in ctDNA or 0-1 DAS score in three consecutive tests in three month intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2 time of trametinib treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with negative status of any mutation in ctDNA or 0-1 DAS score in in five consecutive tests in three month intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib</intervention_name>
    <description>&lt; 6 lat 0,032mg/kg, ≥ 6 lat 0,025mg/kg,</description>
    <arm_group_label>R1 time of trametinib treatment</arm_group_label>
    <arm_group_label>R2 time of trametinib treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Lack of mutations in the BRAF gene in tumor tissues and/or ctDNA at any stage of&#xD;
             treatment or follow-up, or failure of Vemurafenib treatment in BRAF positive patients.&#xD;
&#xD;
          2. Failure of the treatment (at least one of below needs to apply in order for this&#xD;
             requirement to be satisfied):&#xD;
&#xD;
               1. Progression on the I and II line treatment, and involving of a minimum one risk&#xD;
                  organ; previous treatment should include a minimum of 6 weeks of weekly&#xD;
                  Vinblastine with a minimum of 28 days prednisolone or minimum 2 cycles of&#xD;
                  Cytosine Arabinoside in 4-day cycles and/or Cladribine in 5-day cycles as a&#xD;
                  treatment of 2 line, or&#xD;
&#xD;
               2. Disease reactivation after an initial response to treatment with Vimblastine and&#xD;
                  prednisolone as the first line and no response to treatment of the second line&#xD;
                  using a minimum of 2 cycles of one of two drugs: Cytosine Arabinoside in 4-day&#xD;
                  cycles and/or Cladribine in 5-day cycles as a treatment of 2 line and the&#xD;
                  involving of a minimum one risk organ, or&#xD;
&#xD;
               3. Third or subsequent reactivation of disease with or without risk organ&#xD;
                  involvement, or&#xD;
&#xD;
               4. Progression during Vemurafenib therapy, or&#xD;
&#xD;
               5. Reactivation of disease after Vemurafenib therapy has been completed, or&#xD;
&#xD;
               6. The appearance of signs of neurodegenerative disorder (ND) in MRI of the CNS.&#xD;
&#xD;
          3. Signing of informed consent for trial participation (including for Trametinib&#xD;
             treatment) according with current legal regulations.&#xD;
&#xD;
          4. Consent to the use of effective contraception throughout the Trametinib administration&#xD;
             period and a minimum of 1 year after discontinuation in patients at puberty and sexual&#xD;
             maturity.&#xD;
&#xD;
          5. Participation in HISTIOGEN trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lack of inclusion criteria.&#xD;
&#xD;
          2. Pregnancy and breastfeeding .&#xD;
&#xD;
          3. Hypersensitivity to the study drug or any of its ingredients.&#xD;
&#xD;
          4. Iritis, uveitis, obstruction of the retinal veins.&#xD;
&#xD;
          5. Simultaneous treatment with other drugs which might interact with Trametinib.&#xD;
&#xD;
          6. Persistent toxicity related to prior therapy, making it impossible to treat with&#xD;
             Trametinib.&#xD;
&#xD;
          7. Diagnosis of other malignancies before study inclusion.&#xD;
&#xD;
          8. Other acute or persistent disorders, behaviors or abnormal laboratory test results,&#xD;
             which might increase the risk related to the participation in this clinical trial or&#xD;
             to taking the study drug, or which might influence the interpretation of the study&#xD;
             results, or which, in the investigator's opinion, disqualify a patient from&#xD;
             participating in the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anna Raciborska</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mother and Child Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katarzyna Maleszewska</last_name>
    <phone>+48 22 32 77 205</phone>
    <email>klinika.onkologii@imid.med.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mother and Child Institute</name>
      <address>
        <city>Warsaw</city>
        <state>Mazovian</state>
        <zip>01-211</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katarzyna Maleszewska</last_name>
      <phone>+48 22 32 77 205</phone>
      <email>klinika.onkologii@imid.med.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Raciborska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <reference>
    <citation>Cardoso E, Mercier T, Wagner AD, Homicsko K, Michielin O, Ellefsen-Lavoie K, Cagnon L, Diezi M, Buclin T, Widmer N, Csajka C, Decosterd L. Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:124-136. doi: 10.1016/j.jchromb.2018.02.008. Epub 2018 Feb 8.</citation>
    <PMID>29544202</PMID>
  </reference>
  <reference>
    <citation>Cox DS, Allred A, Zhou Y, Infante JR, Gordon MS, Bendell J, Jones S, Burris H 3rd, Orford K. Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors. Clin Pharmacol Drug Dev. 2015 Jul;4(4):287-94. doi: 10.1002/cpdd.152. Epub 2014 Oct 27.</citation>
    <PMID>27136909</PMID>
  </reference>
  <reference>
    <citation>Crombag MBS, van Doremalen JGC, Janssen JM, Rosing H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter? Br J Clin Pharmacol. 2018 Dec;84(12):2770-2778. doi: 10.1111/bcp.13725. Epub 2018 Sep 26.</citation>
    <PMID>30068020</PMID>
  </reference>
  <reference>
    <citation>Farnault L, Hélias-Rodzewicz Z, Venton G, Fanciullino R, Gabriel S, Mescam L, Haroche J, Donadieu J, Emile JF. Response to trametinib of histiocytosis with an activating PTPN11 mutation. Leuk Lymphoma. 2020 Jan;61(1):194-197. doi: 10.1080/10428194.2019.1650175. Epub 2019 Aug 8.</citation>
    <PMID>31393194</PMID>
  </reference>
  <reference>
    <citation>Herbrink M, de Vries N, Rosing H, Huitema ADR, Nuijen B, Schellens JHM, Beijnen JH. Development and validation of a liquid chromatography-tandem mass spectrometry analytical method for the therapeutic drug monitoring of eight novel anticancer drugs. Biomed Chromatogr. 2018 Apr;32(4). doi: 10.1002/bmc.4147. Epub 2017 Dec 19.</citation>
    <PMID>29165815</PMID>
  </reference>
  <reference>
    <citation>Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol. 2012 Aug;13(8):773-81. doi: 10.1016/S1470-2045(12)70270-X. Epub 2012 Jul 16.</citation>
    <PMID>22805291</PMID>
  </reference>
  <reference>
    <citation>Lian T, Li C, Wang H. Trametinib in the treatment of multiple malignancies harboring MEK1 mutations. Cancer Treat Rev. 2019 Dec;81:101907. doi: 10.1016/j.ctrv.2019.101907. Epub 2019 Oct 14. Review.</citation>
    <PMID>31715422</PMID>
  </reference>
  <reference>
    <citation>Lorillon G, Jouenne F, Baroudjian B, de Margerie-Mellon C, Vercellino L, Meignin V, Lebbe C, Vassallo R, Mourah S, Tazi A. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion. Am J Respir Crit Care Med. 2018 Sep 1;198(5):675-678. doi: 10.1164/rccm.201802-0275LE.</citation>
    <PMID>29694792</PMID>
  </reference>
  <reference>
    <citation>Nelson DS, van Halteren A, Quispel WT, van den Bos C, Bovée JV, Patel B, Badalian-Very G, van Hummelen P, Ducar M, Lin L, MacConaill LE, Egeler RM, Rollins BJ. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015 Jun;54(6):361-8. doi: 10.1002/gcc.22247. Epub 2015 Mar 31.</citation>
    <PMID>25899310</PMID>
  </reference>
  <reference>
    <citation>Ouellet D, Kassir N, Chiu J, Mouksassi MS, Leonowens C, Cox D, DeMarini DJ, Gardner O, Crist W, Patel K. Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma. Cancer Chemother Pharmacol. 2016 Apr;77(4):807-17. doi: 10.1007/s00280-016-2993-y. Epub 2016 Mar 3.</citation>
    <PMID>26940938</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institute of Mother and Child, Warsaw, Poland</investigator_affiliation>
    <investigator_full_name>Anna Raciborska</investigator_full_name>
    <investigator_title>Prof Ass</investigator_title>
  </responsible_party>
  <keyword>LCH</keyword>
  <keyword>histiocytosis</keyword>
  <keyword>trametinib</keyword>
  <keyword>paediatric patiens</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histiocytosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

